Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies.

MLA

Russell, Pamela J., et al. “Cytotoxic Properties of Immunoconjugates Containing Melittin-like Peptide 101 against Prostate Cancer: In Vitro and in Vivo Studies.” Cancer Immunology, Immunotherapy, vol. 53, no. 5, May 2004, pp. 411–21. EBSCOhost, https://doi.org/10.1007/s00262-003-0457-9.

APA

Russell, P. J., Hewish, D., Carter, T., Sterling-Levis, K., Ow, K., Hattarki, M., Doughty, L., Guthrie, R., Shapira, D., Molloy, P. L., Werkmeister, J. A., & Kortt, A. A. (2004). Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies. Cancer Immunology, Immunotherapy, 53(5), 411–421. https://doi.org/10.1007/s00262-003-0457-9

Chicago

Russell, Pamela J., Dean Hewish, Teresa Carter, Katy Sterling-Levis, Kim Ow, Meghan Hattarki, Larissa Doughty, et al. 2004. “Cytotoxic Properties of Immunoconjugates Containing Melittin-like Peptide 101 against Prostate Cancer: In Vitro and in Vivo Studies.” Cancer Immunology, Immunotherapy 53 (5): 411–21. doi:10.1007/s00262-003-0457-9.